Literature DB >> 19193629

No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease.

Tamar Farfel-Becker1, Einat Vitner, Hani Dekel, Noa Leshem, Ida Berglin Enquist, Stefan Karlsson, Anthony H Futerman.   

Abstract

Gaucher disease (GD), the most common lysosomal storage disorder (LSD), is caused by defects in the activity of the lysosomal enzyme, glucocerebrosidase, resulting in intracellular accumulation of glucosylceramide (GlcCer). Neuronopathic forms, which comprise only a small percent of GD patients, are characterized by neurological impairment and neuronal cell death. Little is known about the pathways leading from GlcCer accumulation to neuronal death or dysfunction but defective calcium homeostasis appears to be one of the pathways involved. Recently, endoplasmic reticulum stress together with activation of the unfolded protein response (UPR) has been suggested to play a key role in cell death in neuronopathic forms of GD, and moreover, the UPR was proposed to be a common mediator of apoptosis in LSDs (Wei et al. (2008) Hum. Mol. Genet. 17, 469-477). We now systematically examine whether the UPR is activated in neuronal forms of GD using a selection of neuronal disease models and a combination of western blotting and semi-quantitative and quantitative real-time polymerase chain reaction. We do not find any changes in either protein or mRNA levels of a number of typical UPR markers including BiP, CHOP, XBP1, Herp and GRP58, in either cultured Gaucher neurons or astrocytes, or in brain regions from mouse models, even at late symptomatic stages. We conclude that the proposition that the UPR is a common mediator for apoptosis in all neurodegenerative LSDs needs to be re-evaluated.

Entities:  

Mesh:

Year:  2009        PMID: 19193629     DOI: 10.1093/hmg/ddp061

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  23 in total

Review 1.  Pathophysiology of neuropathic lysosomal storage disorders.

Authors:  Cinzia Maria Bellettato; Maurizio Scarpa
Journal:  J Inherit Metab Dis       Date:  2010-04-29       Impact factor: 4.982

Review 2.  Common and uncommon pathogenic cascades in lysosomal storage diseases.

Authors:  Einat B Vitner; Frances M Platt; Anthony H Futerman
Journal:  J Biol Chem       Date:  2010-04-29       Impact factor: 5.157

Review 3.  Endoplasmic-reticulum calcium depletion and disease.

Authors:  Djalila Mekahli; Geert Bultynck; Jan B Parys; Humbert De Smedt; Ludwig Missiaen
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 4.  The pathophysiology of GD - current understanding and rationale for existing and emerging therapeutic approaches.

Authors:  Derralynn A Hughes; Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 5.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

Review 6.  Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses.

Authors:  R Kohan; I A Cismondi; A M Oller-Ramirez; N Guelbert; Tapia V Anzolini; G Alonso; S E Mole; Dodelson R de Kremer; Noher I de Halac
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

Review 7.  Pathology and current treatment of neurodegenerative sphingolipidoses.

Authors:  Matthias Eckhardt
Journal:  Neuromolecular Med       Date:  2010-08-22       Impact factor: 3.843

Review 8.  Modeling neuronopathic storage diseases with patient-derived culture systems.

Authors:  Friederike Zunke; Joseph R Mazzulli
Journal:  Neurobiol Dis       Date:  2019-02-19       Impact factor: 5.996

Review 9.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

10.  Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration.

Authors:  Tamar Farfel-Becker; Einat B Vitner; Samuel L Kelly; Jessica R Bame; Jingjing Duan; Vera Shinder; Alfred H Merrill; Kostantin Dobrenis; Anthony H Futerman
Journal:  Hum Mol Genet       Date:  2013-09-24       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.